

CITATION REPORT

List of articles citing

Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction

DOI: 10.1111/j.1464-5491.2007.02338.x
Diabetic Medicine, 2008, 25, 138-46.

Source: <https://exaly.com/paper-pdf/43709008/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|----|-----------|
| 108 | Current literature in diabetes. 2008 , 24, i-x | | |
| 107 | Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. 2008 , 5, 2160-9 | | 61 |
| 106 | Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. 2008 , 24, 3383-92 | | 35 |
| 105 | Endothelial effects of drugs designed to treat erectile dysfunction. 2008 , 14, 3768-78 | | 24 |
| 104 | Tadalafil in the treatment of erectile dysfunction. 2008 , 4, 1315-30 | | 57 |
| 103 | Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives. 2009 , 3, 105-11 | | 9 |
| 102 | Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. 2009 , 6, 1314-23 | | 55 |
| 101 | Vardenafil allows successful intercourse initiated rapidly after dosing in Japanese patients with diabetes mellitus and erectile dysfunction. 2009 , 6, 2851-7 | | 7 |
| 100 | Emotional changes in men treated with sildenafil citrate for erectile dysfunction: a double-blind, placebo-controlled clinical trial. 2009 , 6, 3469-77 | | 25 |
| 99 | [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. 2009 , 48, 1318, 1320-9 | | 7 |
| 98 | The burden and extent of comorbid conditions in patients with erectile dysfunction. 2009 , 63, 1205-13 | | 42 |
| 97 | A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. 2010 , 105, 1634-9 | | 26 |
| 96 | Likelihood of tadalafil-associated adverse events in integrated multiclinical trial database: classification tree analysis in men with erectile dysfunction. 2009 , 73, 756-61 | | 12 |
| 95 | The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction. 2009 , 10, 155-60 | | 22 |
| 94 | Erectile dysfunction and diabetes mellitus. 2009 , 4, 114-122 | | 14 |
| 93 | Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. 2009 , 181, 245-51 | | 49 |
| 92 | Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. 2009 , 151, 639-49 | | 58 |

| | | |
|----|--|-----|
| 91 | Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. 2009 , 151, 650-61 | 137 |
| 90 | Phosphodiesterase-5 inhibitors: future perspectives. 2009 , 15, 3540-51 | 33 |
| 89 | Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus. 2010 , 127, 189-209 | 58 |
| 88 | Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. 2010 , 57, 804-14 | 722 |
| 87 | Pharmacotherapy for erectile dysfunction. 2010 , 7, 524-40 | 132 |
| 86 | Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. 2010 , 7, 2842-50 | 25 |
| 85 | A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. 2010 , 4, 159-71 | 23 |
| 84 | Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success. 2010 , 22, 1-8 | 13 |
| 83 | Impact of tadalafil once daily in men with erectile dysfunction—including a report of the partnersT evaluation. 2010 , 75, 1358-63 | 22 |
| 82 | Editorial comment. 2010 , 75, 1363-4 | 0 |
| 81 | Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. 2011 , 63, 811-59 | 213 |
| 80 | Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. 2011 , 185, 243-8 | 14 |
| 79 | Screening Informatics and Cheminformatics. 137-156 | |
| 78 | Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. 2011 , 8, 851-64 | 9 |
| 77 | Evaluation of sexual function in hypertensive men receiving treatment: a review of current guidelines recommendation. 2011 , 8, 2405-14 | 19 |
| 76 | A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. 2011 , 8, 2617-24 | 20 |
| 75 | Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. 2011 , 8, 3418-32 | 71 |
| 74 | Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. 2011 , 33, 1590-608 | 10 |

| | | |
|----|--|-----|
| 73 | Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. 2011 , 27, 665-77 | 59 |
| 72 | Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. 2011 , 34, 1669-75 | 234 |
| 71 | Endothelial apoptosis decrease following tadalafil administration in patients with arterial ED does not last after its discontinuation. 2011 , 23, 200-5 | 10 |
| 70 | Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. 2012 , 13, 1481-94 | 15 |
| 69 | Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. 2012 , 38, 1-13 | 85 |
| 68 | Endothelial antioxidant compound prolonged the endothelial antiapoptotic effects registered after tadalafil treatment in patients with arterial erectile dysfunction. 2012 , 33, 170-5 | 7 |
| 67 | Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. 2012 , 33, 1305-22 | 11 |
| 66 | Sexual asthenia: Tradamixina versus Tadalafil 5 mg daily. 2012 , 12 Suppl 1, S23 | 8 |
| 65 | Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. 2012 , 53, 377-85 | 8 |
| 64 | Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil. 2012 , 109, 1060-7 | 14 |
| 63 | Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. 2013 , 10, 551-61 | 29 |
| 62 | Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. 2013 , 15, 475-83 | 42 |
| 61 | Dysfonction Érectile. 2013 , 37, S648 | |
| 60 | Reproductive sequelae of diabetes in male patients. 2013 , 42, 899-914 | 15 |
| 59 | SOP conservative (medical and mechanical) treatment of erectile dysfunction. 2013 , 10, 130-71 | 117 |
| 58 | Erectile dysfunction. 2013 , 37 Suppl 1, S150-2 | 6 |
| 57 | Dysfonction Érectile. 2013 , 37, S528-S530 | |
| 56 | DÉpistage et prise en charge de la dysfonction Érectile des patients diabÉtiques : une nÉcessitÉ pour tout praticien. Revue de littÉrature. 2013 , 22, 3-9 | 2 |

55 Erectile Dysfunction. **2013**, 37, S337

54 Screening and managing erectile dysfunction in diabetic patients (review). **2013**, 22, e1-e8 4

53 Serum High-Sensitivity C-Reactive Protein Levels and Response to 5 mg Tadalafil Once Daily in Patients With Erectile Dysfunction and Diabetes. **2013**, 54, 858-64 8

52 Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. **2013**, 10, 844-56 5

51 Between the Local and the Global: Chronicles for Understanding the Field of Sexology in Mexico. **2013**, 25, 27-46 4

50 A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. **2014**, 11, 820-30 13

49 The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). **2014**, 68, 203-15 68

48 A broad-spectrum approach to daily tadalafil: making the big picture even bigger. **2014**, 65, 465-6

47 Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. **2014**, 65, 455-64 29

46 Sexual dysfunction in diabetes. **2014**, 126, 223-32 33

45 How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. **2014**, 14, 545 34

44 Treatment strategies for diabetic patients suffering from erectile dysfunction: an update. **2014**, 15, 1827-36 21

43 Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use. **2014**, 83, 1334-8 14

42 Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction. **2014**, 83, 1326-33 14

41 Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction. **2015**, 17, 143-8 6

40 Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. **2015**, 172, R103-14 66

39 Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities. **2015**, 15, 111 13

38 Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. **2015**, 31, 379-89 9

| | | |
|----|---|-----|
| 37 | Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily. 2015 , 12, 720-7 | 9 |
| 36 | Erectile dysfunction and its management in patients with diabetes mellitus. 2015 , 16, 213 | 19 |
| 35 | Efficacy of Continuous Dosing of Tadalafil Once Daily vs Tadalafil On Demand in Clinical Subgroups of Men With Erectile Dysfunction: A Descriptive Comparison Using the Integrated Tadalafil Databases. 2016 , 13, 860-75 | 17 |
| 34 | Management of erectile dysfunction in men with diabetes. 2016 , 210-219 | |
| 33 | Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors. 2016 , 4, 270-284 | 11 |
| 32 | Diabetes and Sexual Function. 2016 , 8, 9-18 | 1 |
| 31 | Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). 2016 , 13, 465-88 | 110 |
| 30 | B Cell Lymphoma-2-Modified Bone Marrow-Derived Mesenchymal Stem Cells Transplantation for the Treatment of Diabetes Mellitus-Induced Erectile Dysfunction in a Rat Model. 2017 , 98, 358-366 | 10 |
| 29 | Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥ 5 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. 2017 , 119, 793-803 | 19 |
| 28 | Sexual Dysfunction and Hypogonadism in Men With Diabetes. 2018 , 42 Suppl 1, S228-S233 | 11 |
| 27 | Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. 2018 , 10, 84-92 | 17 |
| 26 | The Efficacy of Tadalafil Daily vs on Demand in the Treatment of Erectile Dysfunction: A Systematic Review and Meta-analysis. 2018 , 112, 6-11 | 7 |
| 25 | [Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities]. 2018 , 16, 28-33 | |
| 24 | The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism. 2018 , 59, 602-613 | 10 |
| 23 | Efficacy and safety of PDE5 inhibitors in the treatment of diabetes mellitus erectile dysfunction: Protocol for a systematic review. 2018 , 97, e12559 | 3 |
| 22 | Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats. 2019 , 11, | 3 |
| 21 | The safety and efficacy of PDE5-inhibitors- vardenafil on treating diabetes mellitus erectile dysfunction: A protocol for systematic review and meta analysis. 2019 , 98, e18361 | 0 |
| 20 | Pharmacodynamics of the agents used for the treatment of erectile dysfunction. 2019 , 15, 121-131 | 3 |

| | | | |
|----|---|-----|----|
| 19 | Effect of prolonged treatment with phosphodiesterase-5-inhibitors on endothelial dysfunction in vascular diseases and vascular risk conditions: A systematic review analysis and meta-analysis of randomized double-blind placebo-controlled trials. 2019 , 73, e13296 | | 4 |
| 18 | Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials. 2019 , 37, 1061-1074 | | 14 |
| 17 | Role of application of tadalafil 5 mg once-daily (8 months) in men with erectile dysfunction from six randomized controlled trials. 2020 , 9, 1405-1414 | | 1 |
| 16 | Correcting imbalance of sex hormones by a phosphodiesterase 5 inhibitor improves copulatory dysfunction in male rats with type 2 diabetes. 2020 , 8, | | 7 |
| 15 | Effects of "metabolic memory" on erectile function in diabetic men: A retrospective case-control study. 2021 , 9, 288-296 | | 1 |
| 14 | Evaluation of daily avanafil efficacy in improving the endothelial function in Egyptian males with erectile dysfunction. <i>Andrologia</i> , 2021 , 53, e13833 | 2.4 | 2 |
| 13 | Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. 2021 , e3494 | | 6 |
| 12 | Sexual Function in Men and Woman with Diabetes. 743-759 | | 1 |
| 11 | Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice. 2020 , 27, 1089-1131 | | 15 |
| 10 | Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. 2015 , 19, 451-61 | | 24 |
| 9 | Erectile Dysfunction. 2010 , 163-179 | | |
| 8 | Erectile Dysfunction. 2015 , 65-116 | | |
| 7 | Daily tadalafil prevents erectile dysfunction in diabetic men. <i>Medscape Journal of Medicine</i> , 2008 , 10, 127 | | 1 |
| 6 | Erectile dysfunction. <i>Clinical Evidence</i> , 2011 , 2011, | | 3 |
| 5 | Role of shear wave elastography (SWE) in erectile dysfunction patients for evaluation of daily tadalafil treatment outcome.. <i>Andrologia</i> , 2022 , e14359 | 2.4 | |
| 4 | Assessment of the intracavernosal injection platelet-rich plasma in addition to daily oral tadalafil intake in diabetic patients with erectile dysfunction non-responding to on-demand oral PDE5 inhibitors.. <i>Andrologia</i> , 2022 , e14421 | 2.4 | 0 |
| 3 | Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study.. <i>Diabetology and Metabolic Syndrome</i> , 2022 , 14, 56 | 5.6 | 0 |
| 2 | Bibliometric and visualization analysis of literature relating to diabetic erectile dysfunction. 13, | | 0 |

- 1 Treatment Outcomes of Diabetic Patients With Erectile Dysfunction Prescribed High-Dose Tadalafil. **2023**,

o